Recently, Maxon et al. reported that mutations in ACK1/TNK2 gene is the main oncogenic cause for AML and chronic myelomonocytic leukemia and that these mutations were sensitive to inhibitors of ACK1 [92]. This evidence concerns the gene TNK2 and acute myeloid leukemia.